Get the Stockscreener App
1.01
0.98%
-0.01
After Hours:
1.03
0.02
+1.98%
Artelo Biosciences Inc stock is traded at $1.01, with a volume of 70,911.
It is down -0.98% in the last 24 hours and down -9.82% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
70,911
Relative Volume:
0.08
Market Cap:
$3.52M
Revenue:
-
Net Income/Loss:
$-13.47M
P/E Ratio:
-0.0259
EPS:
-38.9215
Net Cash Flow:
$-8.38M
1W Performance:
-9.82%
1M Performance:
-9.82%
6M Performance:
-81.50%
1Y Performance:
-97.55%
1-Day Range:
$0.9918
$1.06
1-Week Range:
$0.9918
$1.1626
52-Week Range:
$0.9611
$42.42
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.01 | 3.56M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - marketscreener.com
Review of 50+ CBD studies finds drug interactions in retail products - Stock Titan
Form 4 Artelo Biosciences Inc For: 21 July By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director - Stock Titan
Artelo Biosciences (ARTL) grants small stock option award to director - Stock Titan
Artelo Biosciences grants options to director | ARTL Insider Trading - Stock Titan
Artelo Biosciences Q4 2025 Earnings: EPS Surprises Significantly vs. EstimatesRetail Earnings Report - dars.gov.et
Artelo Biosciences (ARTL) Proxy filing Summary - Quartr
Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies - Stock Titan
Artelo Biosciences (ARTL) AGM 2026 Summary - Quartr
ARTL: All proposals, including director elections and share increases, were approved - TradingView
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo presents preclinical data on osteoarthritis pain drug - Investing.com UK
Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P - GuruFocus
Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions - marketscreener.com
Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen - Quiver Quantitative
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - The Manila Times
These stocks are moving in today's after hours session - ChartMill
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 - The Manila Times
Every Artelo proxy helps reach quorum for July 17 meeting - Stock Titan
Artelo reports positive neuropathic pain study results for ART27.13 - Investing.com UK
Artelo reports ART27.13 pain study results - grafa.com
Artelo Biosciences (ARTL) Reports Positive Findings on Pain Trea - GuruFocus
Artelo reports positive neuropathic pain study results for ART27.13 By Investing.com - Investing.com India
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy - The Manila Times
Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients - Quiver Quantitative
Cancer pain study: ART27.13 eases nerve pain signs in paclitaxel-treated animals - Stock Titan
Artelo Biosciences regains Nasdaq listing compliance - Investing.com
ARTELO BIOSCIENCES INC (ARTL) Stock Chart - ChartMill
ARTLArtelo Biosciences Inc Latest SEC Filings - Finviz
Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus
Artelo Biosciences Announces New Data Support - Moomoo
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Yahoo Finance
Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative
Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models - Stock Titan
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative
Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan
Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView
Artelo Biosciences Inc (ARTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why JOYY shares are trading higher by 12%; here are 20 stocks moving premarket - MSN
Artelo Biosciences (ARTL) Inches Higher Amid Renewed InterestIPO Entry Watch - dars.gov.et
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):